Biogen Idec (BIIB) -5.8% after reporting the failure of its dexpramipexole drug for treating...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen Idec (BIIB) -5.8% after reporting the failure of its dexpramipexole drug for treating people with amyotrophic lateral sclerosis (ALS), which is also known as Lou Gehrig's disease and which affects the nerve cells in the brain and spinal cord that control muscle movement. The medicine didn't meet its primary goals of improving "function and survival," nor did it meet any key secondary endpoints. (PR)